Masthead

nCounter® Human Organ Transplant Panel

Masthead

Are you looking to develop signatures pre- and post-organ transplant to help determine risk of rejection? Then the nCounter Human Organ Transplant Panel is the research tool for you.

Helping Your Research

Panel Development

The Human Organ Transplant Panel was created through a collaboration between NanoString and the Banff Foundation for Allograft Pathology, a global consortium of researchers from multiple prestigious institutes, including researchers from the University of AlbertaErasmus Medical Center RotterdamImperial College LondonMassachusetts General HospitalUniversity of Oxford, and the Paris Transplant Group. The consortium aims to improve organ transplant outcomes through advanced molecular characterization of the in-situ response in the allograft and to make available a transformational new approach for research that can be used to accelerate the identification of new biomarkers of rejection, uncover the mechanisms behind tissue damage, and monitor toxicities brought on by immunosuppressive drugs and infections.

Banff 2019 Meeting Report

Read the Banff 2019 Meeting Report  to learn more about how the content for the Human Organ Transplant panel was created and how the Banff Molecular Diagnostics Working Group (MDWG) plans to maximize data collected using the panel through the formation of a consortium and access to a shared database.

nCounter Human Organ Transplant Panel

How it Works

You can comprehensively profile 770 genes across 37 pathways to identify biomarkers for rejection, uncover the mechanisms of tissue damage, and study toxicities brought on by immunosuppressive drugs.

01:

Study the immune response to transplanted tissue

02:

Discover biomarkers for organ rejection and tissue damage for kidney, heart, liver, and lung

03:

Evaluate immunosuppressive drug pathways

04:

Understand mechanisms behind drug-induced toxicity

05:

Identify BK Polyomavirus, Cytomegalovirus, and Epstein-Barr virus

06:

Quantify the relative abundance of 14 different immune cells

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Functional Annotations
Viral Identification
NHP Compatibility
Product Specifications
Catalog Information
Functional Annotations
Viral Identification

Solid organ and hematopoietic transplant recipients are at increased risk for developing complications from opportunistic viral infections and may even inherit a viral infection from the donor. Knowing if a viral infection is present can be essential to understanding both the immune response and the potential impact of immunosuppressive treatments. Included in the Human Organ Transplant panel are probes specific for the detection of BK Polyomavirus, Cytomegalovirus (CMV) and Epstein-Barr virus (EBV).

NHP Compatibility

Probes included in the Human Organ Transplant Panel have been confirmed to also have high homology to non-human primates providing a valuable tool for translational comparative studies using both human and non-human samples.

Product Specifications
Catalog Information

Related Resources

View All Resources
Product Bulletin Human Organ Transplant Panel – Product Bulletin
Blog Molecular Signatures of Antibody-Mediated Rejection and Graft Outcome After Kidney Transplantation. Q&A with Dr. Dela Golshayan, M.D., Ph.D.
Blog Solid Organ Transplantation and the Immunology of Rejection. Q&A with GeoMx® Digital Spatial Profiler Grant Winner Dr. Fadi Issa
Blog The bench side of organ transplant: Challenges and solutions
Blog Searching for New Biomarkers to Prevent Organ Transplant Rejection. Q&A with HOT Panel Grant Winner Dr. Evan Farkash

NanoString Technology for Human Papillomavirus Typing.

High-throughput HPV typing assays with increased automation, faster turnaround and type-specific digital readout would facilitate studies monitoring the impact of HPV vaccination. We evaluated the NanoString nCounter((R)) platform for detection and digital readout of 48 HPV types in a single reaction.

Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.

PURPOSE: Patients with heterozygous gain-of-function (GOF) mutations in STAT1 frequently exhibit chronic mucocutaneous candidiasis (CMC), immunodeficiency and autoimmune manifestations. Several treatment options including targeted therapies and hematopoietic stem cell transplantation (HSCT) are available for STAT1 GOF patients but modalities and outcomes are not well established.

Tissue-specific endothelial cell heterogeneity contributes to unequal inflammatory responses.

Endothelial cells (EC) coordinate vascular homeostasis and inflammation. In organ transplantation, EC are a direct alloimmune target.

Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us